Ellenberger, David

[["dc.bibliographiccitation.firstpage","1987"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","1997"],["dc.bibliographiccitation.volume","271"],["dc.contributor.author","Engelke, Wilfried G. H."],["dc.contributor.author","Glombek, J."],["dc.contributor.author","Psychogios, Marios Nikos"],["dc.contributor.author","Schneider, S."],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Santander, Petra"],["dc.date.accessioned","2018-11-07T09:38:34Z"],["dc.date.available","2018-11-07T09:38:34Z"],["dc.date.issued","2014"],["dc.description.abstract","Suction ability plays an important role in supporting oral nutrition and needs special care following neurological disorders and tumor-associated defects. However, the details of suction are still poorly understood. The present study evaluates displacement of orofacial structures during suction and deglutition based on manometric controlled MRI. Nine healthy subjects were scanned wearing an intraoral mouthpiece for water intake by suction and subsequent swallowing. Suction-swallowing cycles were identified by intraoral negative pressure. Midsagittal MRI slices (3 T; temporal resolution 0.53 s) were analyzed at rest, suction and pharyngeal swallowing. The mandibular displacement was measured as the distance between the anterior nasal spine and the inferior point of the mandible. Following areas were defined: subpalatal compartment (SCA), retrolingual (RLA), epipharyngeal (EPA) and mouth floor area (MFA). During rest, an average distance of 7 cm was observed between the mandibular measurement points. The measured SCA was 3.67 cm(2), the RLA 6.98 cm(2), the EPA 9.00 cm(2) and the MFA 15.21 cm(2) (average values). At the end of suction, the mandibular distance reduces (to 6.88 cm), the SCA increases significantly (to 5.96 cm(2); p = 0.0002), the RLA decreases (to 6.45 cm(2)), the EPA increases (to 10.59 cm(2)) and the MFA decreases (to 15.02 cm(2)). During deglutition, the mandible lifted significantly (to 6.81 cm; p = 0.0276), the SCA reduced to zero, the RLA was not measurable, the EPA reduces significantly (to 3.01 cm(2); p < 0.0001) and the MFA increases (to 16.36 cm(2)). According to these observations, a combined displacement of the tongue in an anteroposterior direction with active tongue dorsum-velum contact appears to be the predominant activity during suction and responsible for the expansion of the subpalatal area."],["dc.identifier.doi","10.1007/s00405-014-2919-4"],["dc.identifier.isi","000337162100023"],["dc.identifier.pmid","24510235"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33088"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1434-4726"],["dc.relation.issn","0937-4477"],["dc.title","Displacement of oropharyngeal structures during suction-swallowing cycles"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","738"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Genes Chromosomes and Cancer"],["dc.bibliographiccitation.lastpage","749"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Zettl, Andreas"],["dc.contributor.author","Shilo, Konstantin"],["dc.contributor.author","Chuang, Wen-Yu"],["dc.contributor.author","Nicholson, Andrew G."],["dc.contributor.author","Matsuno, Yoshihiro"],["dc.contributor.author","Gal, Anthony"],["dc.contributor.author","Laeng, Rolf Hubert"],["dc.contributor.author","Engel, Peter"],["dc.contributor.author","Capella, Carlo"],["dc.contributor.author","Marino, Mirella"],["dc.contributor.author","Chan, John Kwok-Cheung"],["dc.contributor.author","Rosenwald, Andreas"],["dc.contributor.author","Travis, William D."],["dc.contributor.author","Franks, Teri J."],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Marx, Alexander"],["dc.date.accessioned","2018-11-07T09:36:21Z"],["dc.date.available","2018-11-07T09:36:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Thymic neuroendocrine tumors (TNET) are rare primary epithelial neoplasms of the thymus. This study aimed to determine clinically relevant parameters for their classification and for therapeutic decisions. We performed a comprehensive histological, clinical, and genetic study of 73 TNET cases (13 thymic typical carcinoids [TTC], 40 thymic atypical carcinoids [TAC], and 20 high-grade neuroendocrine carcinomas [HGNEC] of the thymus), contributed by multiple institutions. The mean number of chromosomal imbalances per tumor was 0.8 in TTC (31% aberrant cases) versus 1.1 in TAC (44% aberrant cases) versus 4.7 in HGNEC (75% aberrant cases). Gains of 8q24 (MYC gene locus) were the most frequent alteration and one of the overlapping features between carcinoids and HGNEC. The 5-year survival rates for TTC, TAC, and HGNEC were 100, 60, and 30%. The 10-year survival rates for TTC and TAC were 50 and 30% (P=0.002). Predictive mitotic cut-off values for TTC versus TAC were 2.5 per 10 high-power fields (HPF; indicating a higher death rate, P=0.062) and 15 per 10 HPF (indicating higher risk of recurrence, P=0.036) for separating HGNEC from TAC. We conclude that the current histopathologic classifications of TNET reflect tumor biology and provide important information for therapeutic management. (C) 2014 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/gcc.22183"],["dc.identifier.isi","000339670200003"],["dc.identifier.pmid","24764238"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32598"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-2264"],["dc.relation.issn","1045-2257"],["dc.title","Tumor Genetics and Survival of Thymic Neuroendocrine Neoplasms: A Multi-Institutional Clinicopathologic Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Stork, Lidia"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Lucchinetti, C."],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Metz, Imke"],["dc.date.accessioned","2018-11-07T10:08:49Z"],["dc.date.available","2018-11-07T10:08:49Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Teva Pharma; Biogen; Novartis; Genzyme"],["dc.format.extent","367"],["dc.identifier.isi","000383267201480"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Apheresis therapy in multiple sclerosis patients with histopathologically classified immunopathological patterns"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","461"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","462"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Meissner, Thomas"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Hillert, Jan"],["dc.contributor.author","Buckow, Karoline"],["dc.date.accessioned","2018-11-07T10:08:50Z"],["dc.date.available","2018-11-07T10:08:50Z"],["dc.date.issued","2016"],["dc.identifier.isi","000383267202113"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39544"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Differences in employment of people with MS across Europe"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","587"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Journal of Clinical Investigation"],["dc.bibliographiccitation.lastpage","593"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Buckow, Karoline"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Pitschnau-Michel, Dorothea"],["dc.contributor.author","Fuge, Jan"],["dc.contributor.author","Stueve, Olaf"],["dc.contributor.author","Zettl, Uwe K."],["dc.date.accessioned","2018-11-07T09:56:47Z"],["dc.date.available","2018-11-07T09:56:47Z"],["dc.date.issued","2015"],["dc.description.abstract","BackgroundMultiple Sclerosis is the most common disease in young adults affecting the central nervous system. Disease may progress with acute attacks (relapsing MS) or continuously (progressive MS). Glucocorticosteroids are used in the treatment of acute attacks. The aim of this study was to analyse characteristics of patients with MS, and their influence on current treatment patterns of relapses with glucocorticosteroids. DesignIn 2001, the German National MS Society initiated the German MS-Registry. Patients with relapsing MS were included (n=5106) from this registry. Logistic regression models were used to detect trends over time. The likelihood of administration of steroids is modelled in dependence of calendar year and in dependence to confounders in treatment conditions. The sample size allows that odds ratios can be detected with a power of 90% (alpha=005). ResultsAdministration of glucocorticosteroids was influenced by EDSS (P<00001), age (P<00001) and disease duration (P<00001). Therapy administration in an outpatient setting was more likely in patients with higher EDSS (P<00001) and longer disease duration (P<00001). The utilization of glucocorticosteroids increased with higher EDSS for all relapsing patients. Interestingly, all overutilization of glucocorticosteroids decreased over time and was accompanied by a steadily increased administration of emergent therapeutics. Although there are about 70% of registered patients with relapsing MS on immune-modulatory treatment, almost 60% of them received glucocorticosteroids for treatment of relapses. ConclusionsTreatment patterns with glucocorticosteroids in patients with MS are influenced mainly by EDSS and disease duration. The decline in the utilization of glucocorticosteroids is accompanied by an increase in natalizumab treatment."],["dc.description.sponsorship","Teva Pharmaceuticals"],["dc.identifier.doi","10.1111/eci.12450"],["dc.identifier.isi","000354645200007"],["dc.identifier.pmid","25868705"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37036"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2362"],["dc.relation.issn","0014-2972"],["dc.title","Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis - an observational study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1641"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","1652"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Rommer, Paulus Stefan"],["dc.contributor.author","Eichstädt, Kerstin"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Pöhlau, Dieter"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe Klaus"],["dc.date.accessioned","2020-12-10T18:38:31Z"],["dc.date.available","2020-12-10T18:38:31Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1177/1352458518799580"],["dc.identifier.eissn","1477-0970"],["dc.identifier.issn","1352-4585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77349"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Blood Purification"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Sigler, Matthias"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Gärtner, Jutta"],["dc.contributor.author","Mueller, Gerhard-Anton"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Mühlhausen, Johannes"],["dc.date.accessioned","2017-09-07T11:48:19Z"],["dc.date.available","2017-09-07T11:48:19Z"],["dc.date.issued","2013"],["dc.description.abstract","Background/Aims: In adults, plasma exchange (PE) has been shown to be an efficient treatment for severe relapses of acute inflammatory CNS demyelinating diseases. The aim of this study was to evaluate the safety and efficacy of this treatment in pediatric patients. Methods: We retrospectively analyzed a single-center cohort of pediatric patients with inflammatory CNS demyelinating disorders who underwent apheresis between 2007 and 2011. Results: Ten patients (mean age: 11.6 +/- 3.4 years) with an acute relapse of multiple sclerosis (n = 5), neuromyelitis optica (n = 2) or acute disseminated encephalomyelitis were included. All received methylprednisolone prior to treatment with either PE (n = 5) or immunoadsorption (n = 5). Apheresis-related side effects were either self-limiting or easily managed. EDSS (Expanded Disability Status Scale) improved in 7 of 8 patients during apheresis and in all patients within 30 days from a median of 7.5 to 1 (p < 0.01). The visual acuity initially worsened during the procedure in 3 of 7 affected eyes (mean 0.09), but improved in all at follow-up (mean: 0.5; p = 0.008). Conclusions: Apheresis was well tolerated and associated with a favorable outcome in all pediatric patients similar to reports in adults. Copyright (C) 2013 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000354077"],["dc.identifier.gro","3142409"],["dc.identifier.isi","000328188600005"],["dc.identifier.pmid","24021839"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10815"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7963"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9735"],["dc.relation.issn","0253-5068"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Therapeutic Apheresis in Pediatric Patients with Acute CNS Inflammatory Demyelinating Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","173"],["dc.bibliographiccitation.journal","Multiple Sclerosis and Related Disorders"],["dc.bibliographiccitation.lastpage","174"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Eichstädt, Kerstin"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Pöhlau, Dieter"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe K"],["dc.contributor.author","Rommer, Paulus S"],["dc.date.accessioned","2020-12-10T15:20:23Z"],["dc.date.available","2020-12-10T15:20:23Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.msard.2018.07.040"],["dc.identifier.issn","2211-0348"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72654"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e204"],["dc.bibliographiccitation.firstpage","e204"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neurology: Neuroimmunology & Neuroinflammation"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Pache, Florence"],["dc.contributor.author","Stork, Lidia"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Ruprecht, Klemens"],["dc.contributor.author","Paul, Friedemann"],["dc.date.accessioned","2020-12-10T18:41:40Z"],["dc.date.available","2020-12-10T18:41:40Z"],["dc.date.issued","2016"],["dc.description.abstract","To assess in an observational study whether serum peptide antibody reactivities may distinguish aquaporin-4 (AQP4) antibody (Ab)-positive and -negative neuromyelitis optica spectrum disorders (NMOSD) and relapsing-remitting multiple sclerosis (RRMS)."],["dc.identifier.doi","10.1212/NXI.0000000000000204"],["dc.identifier.eissn","2332-7812"],["dc.identifier.pmid","26894206"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12922"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77646"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2332-7812"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1243"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Statistics"],["dc.bibliographiccitation.lastpage","1261"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Pauly, Markus"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Brunner, Edgar"],["dc.date.accessioned","2018-11-07T09:49:08Z"],["dc.date.available","2018-11-07T09:49:08Z"],["dc.date.issued","2015"],["dc.description.abstract","We propose a novel one sample test for repeated measures designs and derive its limit distribution for the situation where both the sample size n as well as the dimension d of the observations go to infinity. This covers the high-dimensional case with d > n. The tests are based on a quadratic form which involve new unbiased and dimension-stable estimators of different traces of the underlying unrestricted covariance structure. It is shown that the asymptotic distribution of the statistic may be standard normal, standardized chi(2)-distributed, or even of weighted chi(2)-form in some situations. To this end, we suggest an approximation technique which is asymptotically valid in the first two cases and provides an accurate approximation for the latter. We motivate and illustrate the application with a sleep lab data set and also discuss the practical meaning of d -> infinity in case of repeated measures designs. It turns out that the limit behaviour depends on how the number of repeated measures is increased which is crucial for application."],["dc.description.sponsorship","German Research Foundation [DFG-PA 2409/3-1]"],["dc.identifier.doi","10.1080/02331888.2015.1050022"],["dc.identifier.isi","000363326400005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35445"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Ltd"],["dc.relation.issn","1029-4910"],["dc.relation.issn","0233-1888"],["dc.title","Analysis of high-dimensional one group repeated measures designs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]